Evidence map›Paper›PMID 27152859›Full record

ArticleCell cycle (Georgetown, Tex.)2016

Tumor-specific cell-cycle decoy by Salmonella typhimurium A1-R combined with tumor-selective cell-cycle trap by methioninase overcome tumor intrinsic chemoresistance as visualized by FUCCI imaging.

Shuya Yano, Kiyoto Takehara, Ming Zhao, Yuying Tan, Qinghong Han, Shukuan Li, Michael Bouvet, Toshiyoshi Fujiwara, Robert M Hoffman

Abstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Acta biochimica et biophysica Sinica · 2023
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Integration ofCancers · 2021
    Review
  11. Perspectives on OncolyticFrontiers in immunology · 2021
    Review
  12. Use ofFrontiers in oncology · 2021
    Review
  13. Review
  14. Cancers · 2019
    Article
  15. Article
  16. Bugs as Cancer Drugs: Challenges and Opportunities.Molecular and cellular biology · 2019
    Article
  17. Article
  18. Review
  19. Journal of Cancer · 2019
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shuya Yanoa AntiCancer Inc. , San Diego , CA.
Kiyoto Takeharaa AntiCancer Inc. , San Diego , CA.
Ming Zhaoa AntiCancer Inc. , San Diego , CA.
Yuying Tana AntiCancer Inc. , San Diego , CA.
Qinghong Hana AntiCancer Inc. , San Diego , CA.
Shukuan Lia AntiCancer Inc. , San Diego , CA.
Michael Bouvetb Department of Surgery , University of California , San Diego , CA.
Toshiyoshi Fujiwarac Department of Gastroenterological Surgery , Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences , Okayama , Japan.
Robert M Hoffmana AntiCancer Inc. , San Diego , CA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We previously reported real-time monitoring of cell cycle dynamics of cancer cells throughout a live tumor intravitally using a fluorescence ubiquitination cell cycle indicator (FUCCI). Approximately 90% of cancer cells in the center and 80% of total cells of an established tumor are in G0/G1 phase. Longitudinal real-time FUCCI imaging demonstrated that cytotoxic agents killed only proliferating cancer cells at the surface and, in contrast, and had little effect on the quiescent cancer cells. Resistant quiescent cancer cells restarted cycling after the cessation of chemotherapy. Thus cytotoxic chemotherapy which targets cells in S/G2/M, is mostly ineffective on solid tumors, but causes toxic side effects on tissues with high fractions of cycling cells, such as hair follicles, bone marrow and the intestinal lining. We have termed this phenomenon tumor intrinsic chemoresistance (TIC). We previously demonstrated that tumor-targeting Salmonella typhimurium A1-R (S. typhimurium A1-R) decoyed quiescent cancer cells in tumors to cycle from G0/G1 to S/G2/M demonstrated by FUCCI imaging. We have also previously shown that when cancer cells were treated with recombinant methioninase (rMETase), the cancer cells were selectively trapped in S/G2, shown by cell sorting as well as by FUCCI. In the present study, we show that sequential treatment of FUCCI-expressing stomach cancer MKN45 in vivo with S. typhimurium A1-R to decoy quiescent cancer cells to cycle, with subsequent rMETase to selectively trap the decoyed cancer cells in S/G2 phase, followed by cisplatinum (CDDP) or paclitaxel (PTX) chemotherapy to kill the decoyed and trapped cancer cells completely prevented or regressed tumor growth. These results demonstrate the effectiveness of the praradigm of "decoy, trap and shoot" chemotherapy.

Indexed as

Cell CycleUbiquitinationAnimalsAntineoplastic AgentsCarbon-Sulfur LyasesCisplatinDrug Resistance, NeoplasmFluorescenceG2 PhaseHeLa CellsHumansImaging, Three-DimensionalMice, NudeNeoplasmsPaclitaxelRecombinant ProteinsAntineoplastic AgentsCarbon-Sulfur LyasesCisplatinL-methionine gamma-lyasePaclitaxelRecombinant Proteinscancercell-cyclecisplatinumdecoyFUCCImethioninasenude micepaclitaxelSalmonella typhimurium A1-Rstomach cancertrap

Identifiers

PMID27152859
PMCPMC4957602

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.